GMM Pfaudler Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9t2meqjpguu69scy70bzlq0m.pdf

Key Takeaways


Demand & Order Book

Thomas Kehl: "...we are experiencing, not only in Germany but in other countries in Europe, still a shortage of basic medicals, especially treating children. That's why the government to motivate and incentivize the pharmaceutical industries to invest locally in Germany and in other European countries and that will go on for quite a while."

International Business & Acquisitions

Tarak Patel: "So, let's say, for example, if India were to slow down for the next 6-9 months, I'm still confident that the numbers will be met because the international business, with such a larger part of it coming from services and aftermarket, we will still continue to make those numbers."

Margins & Costs


Growth Engines: Mixing, Heavy Engineering & New Technologies


Balance Sheet, Cash Flow & Capital Allocation

Manish Poddar: "We feel, in the next 2 to 3 years, we should generate enough cash. If we don't do any further acquisitions and all that, we should be able to pay off our debt in the next 3 years."

Capacity & Capex

Manish Poddar: "...we generally believe that we can probably do closer to INR 4,000, INR 4,000-plus crores of the turnover out of the existing capex infrastructure that we have."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthGrowth rate to continue in the same region of about 15%Ongoing
FY25 revenueOn track to surpass INR 3,700 croresFY25
FY25 EBITDAINR 630 crores is something "we will definitely do"FY25
FY25 ROCE25%FY25
International margin improvementAt least 100 bps improvement from current ~11%–12%Ongoing
Effective tax rateAround 26%–27% on a go-forward basisOngoing
Chemical & pharma capex cycleOrdering cycle expected to turnMid-2024 to 2025
Hydro Air growthCompany to at least doubleNext 3 years
Mixel growthBusiness to at least doubleNext 3–5 years
Debt repaymentGenerate enough cash to pay off gross debt (~₹800 cr), absent further acquisitionsNext 2–3 years
Promoter stakeCross 25% (awaiting FDI France clearance for 1% DBAG stake)Undated

Key Metrics

MetricQ4 FY23
Revenue₹866 cr, +24% YoY
EBITDA₹96 cr, +34% YoY
EBITDA margin13.6% (FY23), +1.5 ppt YoY
PAT₹235 cr (FY23), 7.4% PAT margin
EPS~₹43 (FY23)
Order intake₹3,392 cr (FY23)
Order backlog₹2,162 cr as of Apr 1, 2023, evenly split between international and India
International business EBITDA margin8.9%, down from 12.7% QoQ (per an analyst's math); would be 0.5 ppt higher excluding new acquisitions
India business EBITDA margin15% (FY23), stable with some pressure from input costs and slower pharma/chem investment
International business revenue growth21% (FY23)
India business revenue growth32% (FY23)
FY25 revenue target₹3,700 cr, on track; existing capex can support closer to ₹4,000+ cr (per an analyst's math)
FY25 EBITDA target₹630 cr, on track
FY25 ROCE target25%
Consolidated net debt-to-EBITDA1x
Net debt-to-equity0.5x
Weighted average cost of capital7.7% global, 8.3% India
Mixing business revenue (India)~₹150 cr (FY23), up from ₹25–30 cr a few years ago
Heavy engineeringBreakeven (FY23); ₹100 cr of orders from one vendor were not margin-accretive
Market share (glass-lined)>50% India, ~40% Europe, 30–35% U.S., ~10% China
Pension liabilities₹280 cr, down from ~₹373 cr at start of FY23 due to interest rate increases
Gross debt~₹800 cr, with ~₹300 cr cash; repayment schedule through FY28
DBAG / Pfaudler Inc. stake14%; 1% acquisition awaiting FDI France clearance, which would take family stake above 25%